Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Short term Debt (2016 - 2025)

Avalo Therapeutics' Short term Debt history spans 8 years, with the latest figure at $370000.0 for Q2 2025.

For Q2 2025, Short term Debt changed N/A year-over-year to $370000.0; the TTM value through Jun 2025 reached $370000.0, changed N/A, while the annual FY2024 figure was $360000.0, N/A changed from the prior year.
Short term Debt reached $370000.0 in Q2 2025 per AVTX's latest filing, up from $360000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $370000.0 in Q2 2025 to a low of $360000.0 in Q4 2024.